Iñigo Rua-Figueroa, Natalia Pérez-Veiga, Esther Rodríguez-Almaraz, María Galindo-Izquierdo, Celia Erausquin, Antonio Fernandez-Nebro, Esther Uriarte Itzazelaia, Belén Serrano-Benavente, Jaime Calvo ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...

Objective BAFF and APRIL signal through TACI, BCMA, and/or BAFF-R, and play important roles in the activation, differentiation, and/or survival of B cells, particularly antibody-secreting cells, as ...

Introduction and purpose Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with SLE, a complex autoimmune disease characterised by loss of tolerance to self-nuclear antigens ...

Background Very limited and old data regarding the epidemiology of juvenile-onset SLE (jSLE) are available. Our aim was to estimate jSLE incidence and mortality rate in incident cases over the period ...

Objective Simple measures of type I interferon (IFN) activity constitute highly attractive biomarkers in systemic lupus erythematosus (SLE). We explore galectin-3-binding protein (G3BP) as a novel ...

Background Antiphospholipid syndrome (APS) is acquired thrombophilia characterized by the presence of antiphospholipid antibodies (aPL). Its main manifestations are vascular thromboses and pregnancy ...

Objectives X chromosome has been considered as a risk factor for SLE, which is a prototype of autoimmune diseases with a significant sex difference (female:male ratio is around 9:1). Our study aimed ...

Methods Blood serum samples, videocapillaroscopy images and patient characteristics were collected in a multicentre longitudinal cSLE cohort and from age and sex comparable HC. Disease activity was ...

Objective We have reported previously that the IRAK4 inhibitor PF06426779 given to ubiquitin-binding-defective ABIN1 [D485N] mice at 6 weeks of age prevents the major facets of lupus that develop 10 ...

Objectives To evaluate the performance of Systemic Lupus Erythematosus Risk Probability Index (SLERPI) in patients with SLE using a Chinese cohort.Methods The Chinese cohort included 352 patients with ...